Objectives. The aim of this study was to conduct a randomized, controlled comparison of outcomes associated with parent/nurse-controlled analgesia (PNCA), with and without a basal (background) opioid infusion, with intravenous (IV) opioids intermittently administered by a nurse on an "as needed" basis (IV PRN) for postoperative pain management in children with developmental delay (DD).
Introduction
Guidelines for the treatment of postoperative pain in children with developmental delay (DD) are often based V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com on provider preference, which can create inconsistent practice and further potentiate the risk of poor pain management for this vulnerable population. Because cognitive impairment associated with DD may impact the ability of children to understand (e.g., understand that pushing a button will improve pain) and/or operate conventional patient-controlled analgesia (PCA), often children with DD are treated with intravenous (IV) analgesics intermittently administered by a nurse on an "as needed" basis (i.e., IV PRN opioids) or with parent-and/ or nurse-controlled analgesia (PNCA) [1, 2] . Although concerns have been raised regarding the safety of PNCA in general [3] , several studies have demonstrated PNCA's safety and efficacy [1, [4] [5] [6] [7] [8] , and many organizations continue to use PNCA for patients unable to operate PCA independently [9] . Additionally, one study found parent activation of PNCA to be as safe as nursecontrolled and conventional patient-controlled analgesia [10] . Despite this, no studies were found that compared outcomes between PNCA and IV PRN opioids in a DD population. Currently, we do not know what impact, if any, the opioid delivery system has on patient outcomes (e.g., pain scores, opioid consumption, and side effects) and whether one delivery system would be better for treating pain in children with DD.
In contrast to opioids delivered by a nurse on an asneeded basis, PNCA can be delivered with or without a basal (background) infusion. However, previous studies regarding the use of a basal rate yield conflicting outcomes. One study of PCA or PNCA use in children found that the addition of a basal infusion decreased overall opioid consumption [11] , whereas others found that the use of a basal infusion increased opioid consumption [12, 13] and another found no effect on opioid consumption [14] . Historically, basal rates have been associated with lower oxygen saturation (SpO 2 ) readings [12, 13] and decreased respiratory rates [13] . A recent meta-analysis on PCA use in pediatric populations found no effect of a basal rate on outcomes, including opioid consumption [15] . The frequency of side effects also differed among the studies; nonetheless none of the studies found the use of a basal rate to improve pain scores [11] [12] [13] [14] . Despite these conflicting results, given the vulnerability of pediatric patients with DD, it is important that we evaluate outcomes such as pain scores, sedation, and side effects associated with IV PRN opioids as well as PNCA with and without basal infusions.
The primary aim of this study was to compare the outcomes associated with three opioid delivery systems-PNCA with basal infusion (PNCA with basal group), PNCA without basal infusion (PNCA without basal group), and IV opioids administered by a nurse on a PRN basis (PRN group)-for postoperative pain management in children with DD. We hypothesized that:
1. Pain scores would be lowest in the PNCA with basal group, followed by the PNCA without basal group, and finally by the PRN group, as measured by the proportion of participants within each group with an average pain (Face, Legs, Activity, Cry, ConsolabilityRevised [FLACC-R]) score of 3 out of 10 (primary outcome).
2. Participants in the PNCA with basal group would consume the most opioid, measured in morphine equivalents (mg/kg/h) for total time on study, followed by participants in the PNCA without basal group, with the least amount of opioid consumed by the PRN group (secondary outcome).
3. Side effects would mirror opioid consumption, such that participants in the PNCA with basal group would experience significantly more side effects than participants in the PNCA without basal group, and the fewest experienced by participants in the PRN group (secondary outcome).
For the purpose of this study, PNCA will refer to situations in which a parent and/or nurse has been instructed and authorized to activate the PCA button on the child's behalf.
Methods
This single-center, prospective, randomized clinical trial was approved by the hospital Human Research and Review Board and was registered at www.clinicaltrials. gov (ID: NCT00743730) by the principal investigator. A portion of this study focused on parent and nurse satisfaction and has been previously published [16] .
Children age four to 18 years who were scheduled for surgery and were expected to require more than a 24-hour stay and IV opioids (based on the surgeon/anesthesiologist's assessment) were screened for enrollment. Inclusion criteria included children with known developmental delay between four and 18 years of age who were unable to operate conventional PCA due to developmental delay. To keep the focus on children receiving PNCA because of DD, children younger than age four years who could receive PNCA because of their age (not because of DD) were excluded. The upper age limit was intended to exclude adult patients. Parents were required to be fluent in English (both speaking and writing) and to verbalize an understanding of and agreement with safety guidelines associated with PNCA.
Exclusion criteria included allergies to both morphine and hydromorphone, the expectation for the child to remain on a ventilator, current use of CPAP/BiPAP, and history of severe snoring and/or episodes of reported sleep apnea.
Medical records for patients who met screening criteria were examined to determine whether patients were/ were not developmentally delayed; patients without indication of DD were excluded. Parents of children whose medical records showed evidence of DD were approached prior to surgery to discuss the study and obtain informed consent. Developmental level was confirmed in person by parent report of previous diagnoses and any testing that may have been performed in the past. Most important in determining whether or not the child was developmentally eligible for the study was the parent's report that the child would be unable to understand and independently operate the PCA device. Because this study enrolled only children with DD, assent was not obtained.
Patients were randomized to one of three groups using a simple randomization scheme: 1) PNCA with basal group, 2) PNCA without basal group, or 3) PRN group. Morphine was used unless the child had an allergy or intolerance, in which case hydromorphone was prescribed. For children randomized into either PNCA group, the PNCA was started in the recovery room or upon arrival to the pediatric intensive care unit (PICU).
No long-acting opioids (e.g., methadone) were used intraoperatively, nor were regional and neuraxial blocks. The Acute Pain Service (APS) followed all patients enrolled in the study. Adjunctive medications (e.g., acetaminophen, nonsteroidal anti-inflammatory medications) were prescribed for all patients, unless contraindicated. Standard PNCA dosing guidelines (in morphine equivalents) were used: The PNCA with basal group received 0.02 mg/kg/dose and basal rate, eight-minute lockout period, 0.12 mg/kg hourly maximum (five doses per hour plus basal rate). The PNCA without basal group received 0.02 mg/kg button dose with an eight-minute lockout and 0.12 mg/kg hourly max (six doses per hour), and the PRN group received 0.08 mg/kg/dose available every two hours PRN [17, 18] . Nurses were to administer the PRN morphine as needed based on their assessment. Parents were to notify their nurse if they believed their child was in pain, which would result in the nurse conducting a pain assessment and administering the morphine if indicated. Although patients in the PNCA groups theoretically could have received more morphine equivalents per hour, in our experience, hourly limits for PNCAs are rarely, if ever, reached, and our previous studies have demonstrated average injections of less than one per hour [4-6]. The parameters used allowed for flexible dosing for the patients. For example, a patient who has slept for several hours may require frequent PNCA doses (0.02 mg/kg) for a short period of time to "catch up," whereas the patient in the PRN group may be "caught up" after just one dose (0.08 mg/ kg). In addition, because of the lockout period of eight minutes and an estimated infusion time of one minute per injection, the hourly maximum of 0.12 mg/kg/h would be titrated over a significantly longer period of time than the PRN dose, thus providing a less dramatic peak in blood levels. To control for practitioner bias, guidelines were in place regarding treatment of side effects or inadequate pain control. For example, the PRN dose, PNCA dose, and basal rate (if in place) were to be decreased by 20% for mild/moderate sedation (sedation scores < 4), whereas the PNCA was to be turned off for two hours if patients experienced significant somnolence (sedation score < 4 and difficulty in arousing). For the PRN group, morphine was not to be administered again until the sedation score was !4, and the dose was to be decreased by 20%. Additional guidelines were given for concerns of increased pain or side effects (e.g., ondansetron for nausea; nalmefene for itching). Once enrolled, children in the PNCA groups were not allowed access to the PNCA button. The intervention was discontinued if requested by a parent or physician or if safety concerns occurred, such as the parent or nurse deviating from the prescribed use of the PNCA device.
Standard patient monitoring and parent education were provided throughout the study. Standard monitoring included sedation and pain assessments a minimum of every four hours, continuous pulse oximetry, and vital signs ordered by the provider as part of a standardized order set. Additionally, as part of routine nursing care, nurses were to discuss signs of pain, instruct parents on the medication (i.e., dose, frequency, potential side effects, etc.), and instruct parents to notify the nurse of any concerns regarding pain control or side effects. For the PNCA groups, nurses were to document the hourly PNCA use in injections delivered and demands attempted and instruct parents to use the PNCA button only when their child was exhibiting signs of pain and never when their child was asleep. This education was also provided by the research nurse during the informed consent process and reinforced by the APS during daily rounds. Parents and nurses were asked to complete satisfaction surveys (results previously reported [16] ).
Data Collection and Time on Study
Data collection began 12 hours after emerging from anesthesia to decrease the impact of anesthetic agents on outcomes. Data are reported for three consecutive 12-hour epochs (reported as epochs 1-3). Side effect data are reported as rates (i.e., number of patients per group who experienced each side effect at any point during epochs 1-3). Data were collected until the patient was ready to transition to enteral analgesics. Data collection included demographic information (i.e., age, gender, race), pain scores (FLACC-Revised pain scale [19] ), opioid consumption, and common opioid side effects.
Measures

Level of Developmental Delay
As in previous studies [1, 4] , the severity of delay was reported by parents and categorized as "mild" (some cognitive delay, but able to communicate effectively), "moderate" (limited communication skills), or "severe" (totally dependent, unable to communicate verbally).
Face, Legs, Activity, Cry, Consolability-Revised Pain Scale
The FLACC-Revised pain scale is a 10-point behavioral pain scale and has demonstrated good criterion and construct validity, as well as interrater reliability in children from four to 19 years of age with DD [19] . The scale measures each of five parameters (Face, Legs, Activity, Cry, and Consolability) from 0 to 2, resulting in a pain score from 0 to 10.
Opioid Consumption
Opioid consumption was reported in standardized morphine equivalents. Hydromorphone use was multiplied by 5 and reported in morphine equivalents [20] .
Sedation
A modified Ramsey scale was used [21] . Nurses reported sedation scores from 1 to 6, with 1 to 3 indicating significant sedation, 4 indicating asleep and easily arouseable or awake but drowsy, 5 indicating normal awake/alert, and 6 indicating anxiety and/or pain higher than baseline. Sedation scores below 4 were considered an indication of somnolence.
Low oxygen saturation (SpO 2 ) was defined as pulse oximetry readings lower than 90%.
Respiratory Depression
Respiratory depression was defined as a respiratory rate of less than 10 breaths per minute for children age four to nine years and fewer than eight breaths per minute for children older than age nine years.
Urinary Retention
Patients were considered to have urinary retention if they had documentation of a urinary catheterization procedure other than placement of a Foley catheter during surgery.
Pruritus and Nausea/Vomiting
Patients were considered to have experienced these side effects if there was documentation of a medication used to treat the side effect.
Statistical Analysis
All analyses based on time periods refer to the first, second, or third 12-hour epochs. Descriptive statistics and plots were used to examine normality of distributions.
Descriptive and frequency analyses were used to provide summary information about patient characteristics. Means (standard deviation) are reported. Where data are skewed, medians and interquartile ranges (IQRs) are reported. Univariate analysis of variance and KruskalWallis tests were used to examine between-group differences. Analyses were conducted using a modified intention to treat (i.e., all patients randomized and receiving the intervention were included and had at least one postrandomization measure). To examine differences in opioid consumption across time, a mixed effects model with maximum likelihood estimation and an autocorrelation matrix (AR (1)) was used. Covariates were race and age. Side effect calculations include data from epochs 1-3. All analyses were calculated using SPSS 22 (IBM SPSS Inc., Chicago, IL, USA). Statistical significance was established at P 0.05.
Power Analysis
An a priori sample size calculation was based on the primary outcome, the proportion of patients in each group with an average pain score of 3 (out of 10) during epoch 1. The study by Czarnecki et al. (2008) on PNCA in pediatric patients with DD showed that the average pain score during the first postsurgical day was 1.0, with a standard deviation of 1.2. With a power of 80%, a type I error rate (alpha) of 0.05, and a two-tailed test, 97 patients would be needed in each group to detect a difference of 0.20 between the PRN group and either of the PNCA groups. These would be compared using a chi-square test.
Results
Demographics
A CONSORT diagram is shown in Figure 1 [22] . Ninetyfour children were enrolled in the study, with 13 children withdrawn before outcomes were measured. Demographic data for the remaining 81 patients are presented in Table 1 . The majority of children were Caucasian (74%), male (58%), with severe cognitive delay (69%), and undergoing orthopedic surgery (41% spinal surgery, 40% other orthopedic surgery) and half (50%) were having surgery for the first time. Across groups, participants did not differ on gender, race, age, weight at time of surgery, surgery type, level of DD, type of preexisting conditions, or whether this was the child's first surgery (all P > 0.05). For one patient in the PNCA with basal group, the intervention was discontinued in epoch 1 (the PNCA was temporarily stopped after naloxone administration and restarted at a slightly lower dose); all outcomes are reported for the study period (intention to treat).
Pain Scores
Pain scores for each group were examined. Average pain scores across epochs 1-3 remained consistently below 2/10 for all groups (medians and IQR shown in Parent/Nurse-Controlled Analgesia RCT Table 2 
Opioid Use
Total opioid consumption was calculated in mg/kg/h (morphine equivalents) for group and epoch ( Figure 3) . Based on the mixed effects model, there was a main effect for group (P < 0.001), but no main effect for time (P ¼ 0.28) and no group Â time interaction (P ¼ 0.44). Specifically, the PNCA with basal group (0.03 mg/kg/h, 0.02-0.03 mg/kg/h) consumed more opioid than the other two groups, with no difference between the PNCA without basal (0.01, 0.00-0.02) and the PRN groups 
Side Effects
Side effects related to opioid consumption were examined across epochs 1-3 (Table 3 ). While the PNCA with basal group consumed significantly more opioid than the other two groups, rates of all side effects were similar across groups. The only differences across groups were minimal: The PRN group had slightly fewer patients with documented oxygen requirements during the study period (P ¼ 0.05) than the PNCA groups.
One patient (4.3% of PNCA with basal group; 1.9% of all PNCA patients; 1.2% of entire sample) required naloxone owing to hypoxia (SpO 2 86%) and respiratory depression (lowest recorded respiratory rate was four breaths per minute). The patient had required 0-1 PNCA doses per hour for four hours and then had a notable increase in PNCA doses (increased to 3-4 doses each hour) along with several dosage adjustments for the following four hours, resulting in 0.12 mg/kg/h for the four-hour period prior to the naloxone administration. Naloxone was administered; the PNCA was turned off for eight hours, and then it was restarted at slightly lower doses.
Discussion
The aim of this RCT was to compare outcomes associated with three opioid delivery systems for postoperative pain management in children with DD in an effort to provide support for a "best practice" recommendation. To our knowledge, this is the first RCT to compare outcomes associated with PNCA, with and without a basal rate, with IV PRN opioids in this population. Contrary to our primary hypothesis, results showed that pain scores in all three groups were low and were unrelated to the opioid delivery system. Consistent with our hypothesis regarding opioid consumption, participants in the PNCA with basal group consumed significantly more opioid than the other two groups. However, side effects did not mirror opioid consumption, as hypothesized. Overall, side effects were equivalent across groups. These results suggest that while all three delivery systems can be used to effectively manage postoperative pain in this population, they also suggest that the basal rate, while contributing to increased opioid consumption, did not result in a significant improvement in pain scores or an increase in side effects.
Surprisingly, average pain scores and the proportion of patients with pain scores 3 did not differ by group despite the PNCA with basal group receiving significantly Figure 2 Opioid consumption (mg/kg/h) for participants with an average pain score of 3 vs ! 4 within each group by epoch. PNCA ¼ parent-and/or nursecontrolled analgesia; PRN ¼ analgesics intermittently administered by a nurse on an "as needed" basis.
more opioid. Overall, the pain scores were quite low, which is comparable with previous studies of PNCA and nurse-controlled analgesia (NCA) [1, 4, 7, 8, 23] . As children with DD are at increased risk for poor pain management [24] , the results of our study showing well controlled pain, regardless of the opioid delivery system, are Figure 3 Opioid consumption (mg/kg/h) by group and epoch. PNCA ¼ parent-and/or nurse-controlled analgesia; PRN ¼ analgesics intermittently administered by a nurse on an "as needed" basis. Table 3 Number of patients with side effects for each group during epochs 1-3 PNCA ¼ parent-and/or nurse-controlled analgesia; PRN ¼ analgesics intermittently administered by a nurse on an "as needed" basis. *Of the 29 patients, four were on home oxygen: two were in the PNCA w/ basal group, one was in the PNCA w/o basal group, and one was in the PRN group. † Standardized residual À1.6, indicating slight underrepresentation of the side effect in the group noted.
reassuring and demonstrate that the three opioid delivery systems are equally good options for pain control.
As with the pain scores, the overall opioid consumption seen in our study was low and similar to other studies of PNCA and NCA [4, 5, 7, 8, 23, 25] . Some previous studies have reported that children with DD received less opioid than children without DD [1, 8] , while others have not found that disparity [2] . In the current study, three results suggest that parents and nurses were administering opioids appropriately. First, and perhaps most importantly, patients with higher mean pain scores received greater amounts of opioids. Secondly, although not significant, opioid consumption decreased across study days for all groups as one would expect, indicating that nurses and parents were not likely administering PNCA doses unnecessarily. Finally, the amount of opioid received did not differ across levels of DD, which is consistent with a previous report [2] . Interestingly, the PRN and PNCA without basal groups received comparable amounts of opioid, which is in contrast to results of an earlier study that showed that children with and without DD who were treated with PCA received more opioid than children in the PRN group [2] .
One of the perceived benefits of PNCA is the convenience and ease of use by parents and nurses. One might expect this convenience to result in increased opioid consumption by both of the PNCA groups as administering opioids on a "PRN" basis by a nurse takes more time and effort. The fact that the PNCA without basal group did not consume more opioid than the PRN group provides further support that across groups parents and nurses were administering opioids appropriately. Furthermore, providers, nurses, and even parents may think patients will receive better pain control with PNCA as the readily available button makes calling and waiting for the nurse unnecessary. While our prior study on parent and nurse satisfaction with this population showed that nurses were more satisfied with PNCA over PRN, parents' satisfaction ratings were high regardless of the opioid delivery system used [16] .
Despite the Institute for Safe Medication Practices (ISMP) urging providers not to use a basal infusion with PCA [26] , basal infusions are common among studies of pediatric PNCA [4- 8, 11] and NCA [23, 25] . The impact of a basal rate on opioid consumption has been inconsistent in previous studies as some have shown an increase in opioid consumption with a basal rate [12, 13, 27] , while another actually showed a decrease in opioid consumption with the use of a basal rate [11] . A recent meta-analysis of PCA in pediatric studies found no differences between PCA with and without a basal on outcomes including pain, opioid consumption, and side effects. However, the authors deem the studies to be of low to very low quality [15] . A recent large-scale retrospective study examined the risk and effectiveness of morphine NCA in children (age 0-18 years) with and without neurodevelopmental disabilities [25] . Results showed that increased morphine consumption was associated with an increased risk of respiratory depression, but only in patients with neurodevelopmental disabilities. In our study, the basal rate contributed to increased opioid consumption without a consequential decrease in pain scores, which begs the question of whether there is any actual benefit to a basal rate. The fact that none of the individual patients in the PNCA with basal group had average pain scores greater than or equal to 4/10 in any epoch suggests one of two possibilities. Perhaps those patients received just enough opioid to keep them from reaching moderate to severe pain, or perhaps they received more medication than necessary by having the basal infusion. However, it does not appear that the presence of a basal rate contributed to oversedation in our sample and our data suggest that, if useful, the basal rate may be important for epoch 1 only, based on the number of patients in both the PNCA without basal and PRN groups with average pain scores !4. As insufficient evidence exists to support scheduled analgesic therapy (without considering pain scores at time of administration) over PRN administration [28] , it stands to reason that basal infusions may not be necessary or beneficial in this patient population. In this small study, the lack of improvement in pain scores with the addition of a basal infusion does not support one opioid delivery system over another.
Common opioid side effects of nausea/vomiting and pruritus were seen in frequencies consistent with previous studies [1, 4, 5, 7] , and the use of a basal infusion in our study did not increase side effects. Although we did not find an increased risk of opioid-induced respiratory depression, as reported by Jay et al. for children with neurodevelopmental delay [25] , the latter data were collected in a retrospective cohort study, and analyses did not include a distinction between PNCA with or without a basal infusion. Overall, previous studies have shown inconsistent findings for the impact of basal infusions on side effects. Studies have shown an increase in hypoxia [12, 13] , no difference in hypoxia [26] ; an increase in nausea [13, 27] and no difference in nausea [11] ; better sleep patterns [27] , and no difference in sedation levels [11] [12] [13] . Taken together with our results, it appears side effects do not consistently vary based on the opioid delivery system and cannot be used to support one opioid delivery system over another.
The most concerning side effect associated with opioid administration, regardless of the opioid delivery system, is respiratory depression significant enough to require naloxone administration. Naloxone was given to one out of 81 patients in this study, a frequency similar to our other studies of PNCA [4, 5] and lower than others [7, 8] .
For this patient, the increased PNCA use, coupled with several dosage adjustments during the four hours prior to naloxone administration, resulted in opioid-induced respiratory depression. Nursing documentation indicated that the patient was awake during this time, and it is unknown if the parent was present. Initially, nursing documentation indicated that the parent had requested the PNCA not be activated until the parent returned.
However, the nurse did activate the PNCA once per hour in the parent's absence. Also of note was that the parent had turned off the pulse oximeter during the night of epoch 2. Together these notations suggest that although the parent had given informed consent and received the PNCA teaching and monitoring guidelines, the parent did not comply. Our overall data continue to suggest that PNCA for children with DD can be safe with appropriate dosing, assessment, monitoring, and parental education, consistent with results from previous studies [4, 5, 7] , and this one patient exemplifies the importance of these safety guidelines.
Although this is the first RCT to report on outcomes associated with PNCA compared with PRN opioids in children with DD, several limitations must be considered. First, our sample size was small and may have been insufficient to detect between-group differences. Patient recruitment was difficult owing to parents' familiarity with PNCA from previous surgeries. Several parents commented that while they agreed with the importance of the study, they were not willing to enroll because they did not want the risk of PRN opioid administration or PNCA without a basal rate. However, the indication is strong that there are no between-group differences in our primary outcome. A post hoc power analysis indicated that to detect the difference of 14.3% found in our primary outcome, based on a comparison of either PNCA group vs PRN with 80% power at an alpha of 0.025, a sample size of 180 (60 per group) would have been needed. Furthermore, despite the recruitment difficulties, we have shown that parents are equally satisfied with all three opioid delivery systems [16] ; therefore, it is unlikely that these difficulties affected our outcomes. Second, generalizability of these findings may be affected by both the staff expertise and by the decision to exclude the first 12-hour postoperative epoch. Our staff is well trained in the care of acute postsurgical pain, and our center uses PNCA (with and without basal) across all patient populations and ages, including our neonatal intensive care unit. Therefore, the results documented here may not generalize to other environments. Further, our decision to exclude the first 12-hour postop period from the data analyses may have impacted our ability to demonstrate between-group differences. We delayed capture of data to allow the anesthetic agents to wear off and for the different analgesic regimens to reach somewhat of a state of equilibrium. As it was impossible to control the individual anesthetic plans given the wide variety of procedures, we felt this method would still allow us to examine differences in analgesic management in the most challenging epochs after surgery, 12-96 hours. Therefore, these data may not generalize to the immediate postoperative period. Finally, this study focused solely on the effects of an opioid delivery system on pain, opioid consumption, and side effects. Therefore, we cannot address the potential influence of these delivery systems on other important outcomes, such as sleep. Given these limitations, to comprehensively evaluate the benefits of delivery systems for this vulnerable population, future studies with larger sample sizes should evaluate the generalizability of our findings, as well as the effects of the delivery systems on other potentially relevant outcomes.
PNCA is frequently used for children with DD; however, results suggest that there may be no advantage over PRN opioids with regard to pain scores, opioid consumption, or side effects. In fact, the addition of a basal rate to the PNCA may increase opioid consumption without improving pain scores. Although nurses preferred PNCA's convenience, rapidity, and parental involvement [16] , the results of the current study coupled with the lack of increased parent satisfaction associated with PNCA [16] suggest that children with DD and their parents may be as comfortable with IV PRN opioids as with PNCA. Therefore, our results do not support a "best practice recommendation" for PNCA. Future studies with larger sample sizes are needed to better ascertain any potential advantage of PNCA with or without the use of a basal rate over PRN opioids.
